Teleflex (TFX) Gets a Buy from RBC Capital

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Teleflex (TFX – Research Report), with a price target of $255.00. The company’s shares closed yesterday at $198.73.

According to TipRanks, Singh Chadha is an analyst with an average return of -1.1% and a 37.84% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Boston Scientific, Johnson & Johnson, and Zynex.

In addition to RBC Capital, Teleflex also received a Buy from JMP Securities’s David Turkaly in a report issued today. However, yesterday, Needham maintained a Hold rating on Teleflex (NYSE: TFX).

TFX market cap is currently $9.95B and has a P/E ratio of 28.08.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teleflex (TFX) Company Description:

Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. Teleflex was founded in 1943 and is headquartered in Wayne, PA.